Soluble urokinase-type Plasminogen Activator Receptor Strongly Predicts Global Mortality in Acute Heart Failure Patients: Insight From the STADE-HF Registry

Abstract

Background: Whether soluble urokinase-type plasminogen activator receptor (suPAR) could be a valuable prognostic indicator remains uncertain. Materials & methods: Patients from STADE-HF (Soluble Suppression of Tumorigenesis-2 as a Help for Management of Diagnosis, Evaluation and Management of Heart Failure) were included for analysis. Results: 95 patients were included. The suPAR level of expression was significantly higher in the group of patients who died at one month (7.90 ± 4.35 ng/ml vs 11.94 ± 6.86 ng/ml; p < 0.05) or 1 year (7.28 ± 4.27 ng/ml vs 11.81 ± 4.88 ng/ml; p < 0.01), but there was no significant difference according to the readmission. Conclusion: High suPAR levels during hospitalization for acute heart failure were highly predictive for the risk of mortality, but not the risk of readmission.

Neural–Cardiac Inflammasome Axis after Traumatic Brain Injury

“…Here, we extended these observations using mass spectrometry analysis to demonstrate that serum EVs after TBI contain myriad inflammasome-, complement-and cardiovascular-related signaling proteins. Some of the proteins found in EVs have been implicated in inflammasome signaling such as the complement C3 [48] and C5 proteins [34], while others are also involved in cardiovascularrelated events like ceruloplasmin [37], clusterin [33], plasminogen [35], kininogen [38] or haptoglobin [36]. In particular, the complement component C3 was abundantly present in serum-derived EVs after TBI.…”

“…We also detected a variety of proteins that have been described to be involved in inflammasome signaling, such as complement C5, serotransferrin, complement factor H, complement C4-B and complement factor B, which were elevated in the TBI group when compared to sham mice (Figure S3C). Finally, we also identified the following signaling proteins that have been shown to be involved in cardiac-related signaling events, such as ceruloplasmin, clusterin, plasminogen, kininogen-1, haptoglobin and inter alpha-trypsin inhibitor heavy chain H2, which were elevated in the TBI group when compared to the sham group (Figure S3D) [33][34][35][36][37][38].…”

Soluble urokinase plasminogen activator receptor and cardiotoxicity in doxorubicin-treated breast cancer patients: a prospective exploratory study

“…Soluble urokinase plasminogen activator (suPAR) is an inflammatory biomarker that robustly predicts adverse cardiovascular events and mortality in patients with cardiovascular disease [ 18 – 20 ]. Furthermore, suPAR is shown to have prognostic utility among cancer patients, particularly breast cancer [ 21 – 24 ].…”

Multimarkers approach in chest pain management in Emergency department: a focus on the prognostic role of sST2 and suPAR

“…They proved that suPAR levels were independently associated with mortality at 1 month and 1 year for patients with acute HF, but without significant prediction of the hospitalization risk and it was a stronger predictor for mortality than other biomarkers (sST2, NT-proBNP or CRP). 34 Bengaard et al described an overall risk of readmission and mortality significantly increased for patients with higher suPAR, 55 while Al-Badri et al showed that high suPAR and hsTnI levels were independently associated with a higher risk of all cause death and MACE. 56 Moreover, hs-CRP, NT-proBNP, and suPAR showed different associations with cardiovascular death among apparently healthy younger and older men and women.…”

“…33 Furthermore, in the STADE-HF study, an ancillary study of a randomized trial: NCT02963272, sST2 showed to be better associated with the risk of hospitalization when compared to suPAR, which, in contrast, resulted associated with long term mortality. 34 It was also revealed that sST2-guided therapy does not decrease readmissions. This study was aimed to evaluate a sST2-guided treatment in patients hospitalized for acute HF.…”